Video: How many PD-1/L1 drugs do we need? Where is immunotherapy headed? Watch Jay Bradner, Hervé Hoppenot, Ellen Sigal, David Berman, Gideon Blumenthal, and Aiman Shalabi discuss with Endpoints at #JPM18
SAN FRANCISCO — In front of a packed house on Tuesday at the Endpoints News breakfast panel during #JPM18, Aiman Shalabi, CMO at the Cancer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
